HWAM
KDNY

Hennion & Walsh Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Hennion & Walsh Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-40,219
Closed -$1.54M – 850
2023
Q2 		$1.54M Buy
40,219
+3,273
+9% +$84K 0.09% 270
2023
Q1 		$855K Buy
36,946
+10,574
+40% +$252K 0.05% 394
2022
Q4 		$691K Buy
+26,372
New +$584K 0.04% 419

Hennion & Walsh Asset Management's KDNY Position: Q3 2023 in Review

Hennion & Walsh Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 40,219 shares — an estimated $1.54M sold.

Hennion & Walsh Asset Management first reported a position in KDNY in Q4 2022 and held it in 3 quarters. The position peaked at $1.54M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Hennion & Walsh Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 40,219 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.54M.
  • Hennion & Walsh Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Hennion & Walsh Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.54M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q3 2023, filed 27 Oct 2023.